title: Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(L)lysine-alginate membrane.
abstract: Cytomedical therapy for human interleukin-6 transgenic mice (hIL-6 Tgm) was implemented by the intraperitoneal injection of alginate-poly(L)lysine-alginate (APA) membranes microencapsulating SK2 hybridoma cells (APA-SK2 cells) which secrete anti-hIL-6 monoclonal antibodies (SK2 mAb). IgG1 plasmacytosis in the hIL-6 Tgm was suppressed by a single injection of APA-SK2 cells, and the survival time of these mice was remarkably prolonged. The viable cell number and the SK2 mAb-secretion of APA-SK2 cells increased for at least one month both under culture conditions and in allogeneic recipients (in vivo). Moreover, SK2 mAb which were secreted from APA-SK2 cells injected into allogeneic recipients was detected in serum at high concentrations; 3-5 mg/ml from day 14 to day 50 post-injection. In contrast, the injection of free SK2 cells had no therapeutic effect on hIL-6 Tgm. These results strongly suggest that APA membranes microencapsulating cells which were modified to secrete molecules useful for the treatment of a disorder were effective as an in vivo long-term delivery system of bioactive molecules, as 'cytomedicine'.
authors.affiliation: Faculty and Graduate School of Pharmaceutical Sciences, Osaka University, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Yoshioka
authors.forename: A
authors.initials: A
authors.lastname: Katsume
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: K
authors.initials: K
authors.lastname: Yorozu
authors.forename: O
authors.initials: O
authors.lastname: Ueda
authors.forename: N
authors.initials: N
authors.lastname: Itoh
authors.forename: H
authors.initials: H
authors.lastname: Mizuguchi
authors.forename: S
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ohsugi
authors.forename: T
authors.initials: T
authors.lastname: Mayumi
mesh_terms: D000464:Alginates; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002455:Cell Division; D002470:Cell Survival; D017690:Cell Transplantation; D002478:Cells, Cultured; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood*; D015850:Interleukin-6 / Q000276:immunology*; D008218:Lymphocytosis / Q000628:therapy*; D008567:Membranes, Artificial; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D009929:Organ Size; D010950:Plasma Cells; D011107:Polylysine / Q000031:analogs & derivatives; D013154:Spleen / Q000473:pathology
chemical_list: D000464:Alginates; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D015850:Interleukin-6; D008567:Membranes, Artificial; C051546:alginate-polylysine-alginate; D011107:Polylysine